Editorial Note on Interferon and GvHD

For patients with hematological malignancies, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most successful and curative therapy option. Graft-versus-leukemia (GvL) effects and robust immunological reconstitution are two of the life-saving advantages of all-HSCT. The majority of patients, however, suffer Graft-vs-Host Disease (GvHD), which causes organ/tissue destruction in the skin, liver, and gastrointestinal system. As a result, substantial study on GvHD has been conducted, with IFNs being identified as a therapeutic target. Despite this, the pleiotropic nature of IFNs has hampered our efforts to achieve optimal GvHD management.

Author(s): Charles Martins

Abstract | PDF

Share This Article